VERU
Veru Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.64
−0.38%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 16.9M | 16.3M | 39.4M |
| Cost of Revenue | 56.4K | — | 11.0M | 8.7M | 8.8M |
| Gross Profit | (56.4K) | — | 5.9M | 7.6M | 30.6M |
| Operating Expenses | |||||
| R&D Expense | 11.8M | 15.6M | 12.8M | 51.2M | 70.6M |
| SG&A Expense | 16.1M | 19.9M | 31.2M | 48.1M | 43.2M |
| General & Admin Expense | 25.3M | 19.9M | 31.2M | 48.1M | 43.2M |
| Selling & Marketing Expense | (9.3M) | — | — | — | — |
| Other Expenses | (8.7M) | (10.8M) | (1.2M) | 2.1M | — |
| Total Operating Expenses | 19.2M | 24.8M | 42.8M | 101.3M | 113.8M |
| Cost and Expenses | 19.2M | 24.8M | 53.8M | 110.1M | 122.6M |
| Operating Income (EBIT) | (19.2M) | (24.8M) | (36.9M) | (93.8M) | (83.2M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | 607.5K | 2.4M | 4.4M |
| Net Interest Income | — | — | (607.5K) | (2.4M) | (4.4M) |
| Other Non-Op Income/Expense | 5.1M | 9.1M | (160.9K) | 1.1M | (580.7K) |
| Non-Operating Income (excl Interest) | 7.9M | 10.8M | (446.5K) | (3.5M) | (4.1M) |
| EBT (Pre-Tax Income) | (14.1M) | (15.7M) | (37.1M) | (92.7M) | (83.8M) |
| Income Tax Expense | — | — | 725.1K | 480.2K | 236.4K |
| Bottom Line | |||||
| Net Income | (13.6M) | (22.7M) | (37.8M) | (93.2M) | (83.8M) |
| Earnings from Cont. Ops | (14.1M) | (15.7M) | (37.8M) | (93.2M) | (84.0M) |
| Earnings from Discont. Ops | 500.8K | (7.0M) | — | — | — |
| Bottom Line Net Income | (13.6M) | (22.7M) | (37.8M) | (93.2M) | (84.0M) |
| Per Share | |||||
| Basic EPS | ($0.60) | ($1.55) | ($2.80) | ($10.96) | ($10.49) |
| Diluted EPS | ($0.60) | ($1.55) | ($2.80) | ($10.96) | ($10.49) |
| Revenue Per Share | $0.00 | $0.00 | $1.25 | $1.92 | $4.91 |
| Shares | |||||
| Basic Shares Outstanding | 23.1M | 14.6M | 13.5M | 8.5M | 8.0M |
| Diluted Shares Outstanding | 23.1M | 14.6M | 13.5M | 8.5M | 8.0M |
| Profitability Metrics | |||||
| EBITDA | (27.0M) | (35.4M) | (36.2M) | (90.0M) | (79.2M) |
| D&A | 85.0K | 152.1K | 268.2K | 269.9K | 209.6K |
| EBIT | (27.1M) | (35.5M) | (36.5M) | (90.2M) | (79.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026